Evaluation of the MD Anderson tumor score for diffuse large B‐cell lymphoma in the rituximab era

OBJECTIVES: Diffuse large B‐cell lymphoma (DLBCL) is an aggressive heterogeneous lymphoma with standard treatment. However, 30%‐40% of patients still fail, so we should know which patients are candidates for alternative therapies. IPI is the main prognostic score but, in the rituximab era, it cannot...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Haematol
Main Authors: Gutierrez, Antonio, Bento, Leyre, Diaz‐Lopez, Antonio, Barranco, Gilberto, Garcia‐Recio, Marta, Lopez‐Guillermo, Armando, Dlouhy, Ivan, Rovira, Jordina, Rodriguez, Mario, Sanchez Pina, Jose María, Baile, Monica, Martín, Alejandro, Novelli, Silvana, Sancho, Juan‐Manuel, García, Olga, Salar, Antonio, Bastos‐Oreiro, Mariana, Rodriguez‐Salazar, Mª José, Fernandez, Ruben, de la Cruz, Fatima, Queizan, Jose Antonio, González de Villambrosia, Sonia, Cordoba, Raul, López, Andres, Luzardo, Hugo, García, Daniel, Sastre‐Serra, Jordi, Garcia, Juan Fernando, Montalban, Carlos, Cabanillas, Fernando, Rodríguez, Jose
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley and Sons Inc. 2020
Fag:
Original Articles
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7217048/
https://ncbi.nlm.nih.gov/pubmed/31804029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ejh.13364
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker